NHS England's Tirzepatide Rollout: What the Evidence and Guidance Actually Say

What NICE TA1026 actually recommends, and why phasing exists

NICE's appraisal of tirzepatide, published on 23 December 2024 and updated on 1 September 2025, is the foundation of the NHS England rollout. The committee reviewed the clinical trial programme (including the SURMOUNT-1 data showing average body-weight reductions of around 20–21% over 72 weeks at the highest dose) and concluded that tirzepatide represented good value for the NHS when targeted at people with the highest clinical need. You can read the full recommendations at NICE's tirzepatide appraisal (TA1026).

Phasing exists for practical reasons. Commissioning at scale takes time, and NHS England chose to sequence access by severity, opening to those with the most complex health profiles first. That means the rollout is not a waiting list in the traditional sense, it is a series of eligibility thresholds, each unlocking on a published approximate date. Knowing where you sit in that sequence is genuinely useful information.

From 1 April 2026, GP practices may prescribe tirzepatide under the new GP contract (QOF 2026/27), though participation is optional and availability varies between practices and areas. A referral to a specialist service is no longer a requirement for all cohorts, which is a meaningful change for many patients.

Which cohorts are open right now, and who the 2027 phase covers

The first cohort went live in June 2025. It requires a BMI of 40 or above alongside four or more of five specified conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. That is a high bar, deliberately so.

The second cohort activated on 23 June 2026, extending eligibility to adults with a BMI of 35–39.9 who also have four or more of those same conditions. For people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds, the BMI thresholds throughout the rollout are 2.5 kg/m² lower.

A third cohort is expected from around March 2027, reducing the qualifying condition count to three for people with a BMI of 40 or above. NHS England's weight management injections guidance sets out the wraparound care requirements (structured dietary support and physical activity coaching) that accompany every NHS prescription. Those support requirements apply regardless of which cohort a person enters.

If you're close to a threshold but not quite there yet, the honest answer is that the 2027 cohort is still some way off, and the conditions requirement remains high throughout.

The gap between NHS criteria and what the medicine is licensed for

This is probably where most readers land. Tirzepatide's UK licence covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. That is considerably broader than the NHS criteria. Someone with a BMI of 33 and well-controlled hypertension is within the licensed population for the medicine, but outside every NHS cohort that is currently open.

That gap is real, and it is the reason private prescription routes exist. A regulated online pharmacy operating within the licensed criteria can offer a prescriber assessment to people who don't meet NHS thresholds, can't access a GP who is participating in the scheme, or simply don't want to wait. If you're thinking about that route, the most important thing is verifying that the pharmacy is GPhC-registered, and our guide on where you can safely buy Mounjaro explains exactly what to look for and which red flags to avoid. For more on the private route and what a clinical assessment involves, the process for getting tirzepatide privately sets it out step by step.

Cost is a fair question at this point. The landscape changed in September 2025, when Eli Lilly raised the UK list price significantly, the highest dose's list price moved from around £122 to around £330 per four-week pen, with typical private market prices running roughly £149–£375 per month by dose and provider. If you are ready to move to the highest strength, you can find out more about how to buy tirzepatide 15mg, including what the prescribing assessment covers at that dose. There's a more detailed breakdown of what private pricing actually covers on the Mounjaro cost page.

Stock, supply and what to expect from a private pharmacy

One topic that comes up frequently in the context of the NHS rollout is supply. As NHS volumes increase, the question of whether private stock is affected is reasonable. The short answer is that tirzepatide availability has generally remained more stable in the private licensed supply chain than some early reports suggested, though it is worth confirming the position at the point of ordering.

At nume, every prescription goes through a same-day review by a GPhC-registered Independent Prescriber, not automated software. Identity and weight are verified before any prescription is issued, and treatment is dispensed from our own GPhC-registered pharmacy. If you order before midday on a working day and your consultation is approved, your pen is dispatched the same day and arrives free via DPD the next working day. If you'd like to find out whether you're clinically eligible, start your free consultation and a prescriber will review your answers the same day.